Clinical trial simulation to evaluate population pharmacokinetics and food effect: Capturing abiraterone and nilotinib exposures

Claire H. Li, Eric A. Sherer, Lionel D. Lewis, Robert Bies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The objectives of this study were to determine (1) the accuracy with which individual patient level exposure can be determined and (2) whether a known food effect can be identified in a trial simulation of a typical population pharmacokinetic trial. Clinical trial simulations were undertaken using NONMEM VII to assess a typical oncology pharmacokinetic trial design. Nine virtual trials for each compound were performed for combinations of different levels of between-occasion variability, number of patients in the trial, and magnitude of a food covariate on oral clearance. Less than 5% and 20% bias and precision were obtained in individual clearance estimated for both abiraterone and nilotinib using this design. This design resulted in biased and imprecise population clearance estimates for abiraterone. The between-occasion variability in most trials was captured with less than 30% of percent bias and precision. The food effect was detectable as a statistically significant covariate on oral clearance for abiraterone and nilotinib with percent bias and precision of the food covariate less than 20%. These results demonstrate that clinical trial simulation can be used to explore the ability of specific trial designs to evaluate the power to identify individual and population level exposures, covariate, and variability effects.

Original languageEnglish (US)
Pages (from-to)556-562
Number of pages7
JournalJournal of Clinical Pharmacology
Volume55
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Pharmacokinetics
Clinical Trials
Food
Population
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
abiraterone

Keywords

  • abiraterone
  • clinical trial simulation
  • nilotinib
  • population pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Clinical trial simulation to evaluate population pharmacokinetics and food effect : Capturing abiraterone and nilotinib exposures. / Li, Claire H.; Sherer, Eric A.; Lewis, Lionel D.; Bies, Robert.

In: Journal of Clinical Pharmacology, Vol. 55, No. 5, 01.05.2015, p. 556-562.

Research output: Contribution to journalArticle

@article{0cc69d55de494c11ad71a42c336b041a,
title = "Clinical trial simulation to evaluate population pharmacokinetics and food effect: Capturing abiraterone and nilotinib exposures",
abstract = "The objectives of this study were to determine (1) the accuracy with which individual patient level exposure can be determined and (2) whether a known food effect can be identified in a trial simulation of a typical population pharmacokinetic trial. Clinical trial simulations were undertaken using NONMEM VII to assess a typical oncology pharmacokinetic trial design. Nine virtual trials for each compound were performed for combinations of different levels of between-occasion variability, number of patients in the trial, and magnitude of a food covariate on oral clearance. Less than 5{\%} and 20{\%} bias and precision were obtained in individual clearance estimated for both abiraterone and nilotinib using this design. This design resulted in biased and imprecise population clearance estimates for abiraterone. The between-occasion variability in most trials was captured with less than 30{\%} of percent bias and precision. The food effect was detectable as a statistically significant covariate on oral clearance for abiraterone and nilotinib with percent bias and precision of the food covariate less than 20{\%}. These results demonstrate that clinical trial simulation can be used to explore the ability of specific trial designs to evaluate the power to identify individual and population level exposures, covariate, and variability effects.",
keywords = "abiraterone, clinical trial simulation, nilotinib, population pharmacokinetics",
author = "Li, {Claire H.} and Sherer, {Eric A.} and Lewis, {Lionel D.} and Robert Bies",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/jcph.449",
language = "English (US)",
volume = "55",
pages = "556--562",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical trial simulation to evaluate population pharmacokinetics and food effect

T2 - Capturing abiraterone and nilotinib exposures

AU - Li, Claire H.

AU - Sherer, Eric A.

AU - Lewis, Lionel D.

AU - Bies, Robert

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The objectives of this study were to determine (1) the accuracy with which individual patient level exposure can be determined and (2) whether a known food effect can be identified in a trial simulation of a typical population pharmacokinetic trial. Clinical trial simulations were undertaken using NONMEM VII to assess a typical oncology pharmacokinetic trial design. Nine virtual trials for each compound were performed for combinations of different levels of between-occasion variability, number of patients in the trial, and magnitude of a food covariate on oral clearance. Less than 5% and 20% bias and precision were obtained in individual clearance estimated for both abiraterone and nilotinib using this design. This design resulted in biased and imprecise population clearance estimates for abiraterone. The between-occasion variability in most trials was captured with less than 30% of percent bias and precision. The food effect was detectable as a statistically significant covariate on oral clearance for abiraterone and nilotinib with percent bias and precision of the food covariate less than 20%. These results demonstrate that clinical trial simulation can be used to explore the ability of specific trial designs to evaluate the power to identify individual and population level exposures, covariate, and variability effects.

AB - The objectives of this study were to determine (1) the accuracy with which individual patient level exposure can be determined and (2) whether a known food effect can be identified in a trial simulation of a typical population pharmacokinetic trial. Clinical trial simulations were undertaken using NONMEM VII to assess a typical oncology pharmacokinetic trial design. Nine virtual trials for each compound were performed for combinations of different levels of between-occasion variability, number of patients in the trial, and magnitude of a food covariate on oral clearance. Less than 5% and 20% bias and precision were obtained in individual clearance estimated for both abiraterone and nilotinib using this design. This design resulted in biased and imprecise population clearance estimates for abiraterone. The between-occasion variability in most trials was captured with less than 30% of percent bias and precision. The food effect was detectable as a statistically significant covariate on oral clearance for abiraterone and nilotinib with percent bias and precision of the food covariate less than 20%. These results demonstrate that clinical trial simulation can be used to explore the ability of specific trial designs to evaluate the power to identify individual and population level exposures, covariate, and variability effects.

KW - abiraterone

KW - clinical trial simulation

KW - nilotinib

KW - population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84961363761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961363761&partnerID=8YFLogxK

U2 - 10.1002/jcph.449

DO - 10.1002/jcph.449

M3 - Article

C2 - 25511575

AN - SCOPUS:84961363761

VL - 55

SP - 556

EP - 562

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 5

ER -